Kim K, Choi B, Kim K, Park K, Lee H, Cho Y
AIDS Res Hum Retroviruses. 2015; 32(2):194-202.
PMID: 26564392
PMC: 4761813.
DOI: 10.1089/AID.2015.0211.
Sui Y, Gordon S, Franchini G, Berzofsky J
Curr Protoc Immunol. 2014; 102:12.14.1-12.14.30.
PMID: 24510515
PMC: 3920465.
DOI: 10.1002/0471142735.im1214s102.
Shedlock D, Silvestri G, Weiner D
Nat Rev Immunol. 2009; 9(10):717-28.
PMID: 19859066
PMC: 4317297.
DOI: 10.1038/nri2636.
Andersen J, Le Rouzic E, Planelles V
Exp Mol Pathol. 2008; 85(1):2-10.
PMID: 18514189
PMC: 2610539.
DOI: 10.1016/j.yexmp.2008.03.015.
DeHart J, Planelles V
J Virol. 2007; 82(3):1066-72.
PMID: 17855541
PMC: 2224437.
DOI: 10.1128/JVI.01628-07.
Vaccine protection against a heterologous, non-syncytium-inducing, primary human immunodeficiency virus.
Robert-Guroff M, Kaur H, Patterson L, Leno M, Conley A, McKenna P
J Virol. 1998; 72(12):10275-80.
PMID: 9811775
PMC: 110613.
DOI: 10.1128/JVI.72.12.10275-10280.1998.
Extensive diversification of human immunodeficiency virus type 1 subtype B strains during dual infection of a chimpanzee that progressed to AIDS.
Wei Q, Fultz P
J Virol. 1998; 72(4):3005-17.
PMID: 9525623
PMC: 109748.
DOI: 10.1128/JVI.72.4.3005-3017.1998.
Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines.
Connor R, Korber B, Graham B, Hahn B, Ho D, Walker B
J Virol. 1998; 72(2):1552-76.
PMID: 9445059
PMC: 124637.
DOI: 10.1128/JVI.72.2.1552-1576.1998.
Induction of neutralizing antibodies to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime-boost vaccine regimen in chimpanzees.
Zolla-Pazner S, Lubeck M, Xu S, Burda S, Natuk R, Sinangil F
J Virol. 1998; 72(2):1052-9.
PMID: 9444999
PMC: 124577.
DOI: 10.1128/JVI.72.2.1052-1059.1998.
Studies of AIDS vaccination using an ex vivo feline immunodeficiency virus model: protection conferred by a fixed-cell vaccine against cell-free and cell-associated challenge differs in duration and is not easily boosted.
Matteucci D, Pistello M, Mazzetti P, Giannecchini S, Del Mauro D, Lonetti I
J Virol. 1997; 71(11):8368-76.
PMID: 9343192
PMC: 192298.
DOI: 10.1128/JVI.71.11.8368-8376.1997.
Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus.
Shibata R, Siemon C, Czajak S, Desrosiers R, Martin M
J Virol. 1997; 71(11):8141-8.
PMID: 9343164
PMC: 192270.
DOI: 10.1128/JVI.71.11.8141-8148.1997.
Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated simian immunodeficiency virus.
Johnson R, Glickman R, Yang J, Kaur A, Dion J, Mulligan M
J Virol. 1997; 71(10):7711-8.
PMID: 9311855
PMC: 192122.
DOI: 10.1128/JVI.71.10.7711-7718.1997.
Development of AIDS in a chimpanzee infected with human immunodeficiency virus type 1.
Novembre F, Saucier M, Anderson D, Klumpp S, ONeil S, Brown 2nd C
J Virol. 1997; 71(5):4086-91.
PMID: 9094687
PMC: 191562.
DOI: 10.1128/JVI.71.5.4086-4091.1997.
Resistance of human immunodeficiency virus type 1 to neutralization by natural antisera occurs through single amino acid substitutions that cause changes in antibody binding at multiple sites.
Watkins B, Buge S, Aldrich K, Davis A, Robinson J, Reitz Jr M
J Virol. 1996; 70(12):8431-7.
PMID: 8970964
PMC: 190932.
DOI: 10.1128/JVI.70.12.8431-8437.1996.
Salivary binding antibodies induced by human immunodeficiency virus type 1 recombinant gp120 vaccine. The NIAID AIDS Vaccine Evaluation Group.
Gorse G, Yang E, Belshe R, BERMAN P
Clin Diagn Lab Immunol. 1996; 3(6):769-73.
PMID: 8914773
PMC: 170445.
DOI: 10.1128/cdli.3.6.769-773.1996.
Failure of a human immunodeficiency virus type 1 (HIV-1) subtype B-derived vaccine to prevent infection of chimpanzees by an HIV-1 subtype E strain.
Girard M, Yue L, Barre-Sinoussi F, van der Ryst E, Meignier B, Muchmore E
J Virol. 1996; 70(11):8229-33.
PMID: 8892959
PMC: 190908.
DOI: 10.1128/JVI.70.11.8229-8233.1996.
The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate.
Conley A, Kessler 2nd J, Boots L, McKenna P, Schleif W, Emini E
J Virol. 1996; 70(10):6751-8.
PMID: 8794312
PMC: 190718.
DOI: 10.1128/JVI.70.10.6751-6758.1996.
Resistance of previously infected chimpanzees to successive challenges with a heterologous intraclade B strain of human immunodeficiency virus type 1.
Shibata R, Siemon C, Cho M, Arthur L, Nigida Jr S, Matthews T
J Virol. 1996; 70(7):4361-9.
PMID: 8676459
PMC: 190369.
DOI: 10.1128/JVI.70.7.4361-4369.1996.
HIV preventive vaccines. Progress to date.
Esparza J, Osmanov S, Heyward W
Drugs. 1995; 50(5):792-804.
PMID: 8586027
DOI: 10.2165/00003495-199550050-00003.
Where are we now with vaccines against AIDS?.
Schild G, Stott E
BMJ. 1993; 306(6883):947-8.
PMID: 8490466
PMC: 1677453.
DOI: 10.1136/bmj.306.6883.947.